RESUMO
The present work is aimed at studying acute oral toxicity (AOT), subchronic oral toxicity, mutagenicity, and genotoxicity of furostanol glycosides-based standardized fenugreek seed extract (Fenu-FG) using the Organization for Economic Co-operation and Development (OECD) guidelines. The AOT and subchronic (90-day repeated dose) toxicity studies were performed on Wistar rats as per OECD 423 and OECD 408 guidelines, respectively. The mutagenicity (reverse mutation assay, Ames test) and genotoxicity (mammalian chromosome aberration test) were assessed in vitro using OECD 471 and OECD 473 guidelines, respectively. At an acute oral limit dose of 2,000 mg/kg, Fenu-FG did not show any mortality or treatment-related adverse signs. Ninety days of subchronic oral administration of Fenu-FG (250, 500, or 1,000 mg/kg) in rats did not induce any treatment-related significant changes with respect to body weight, hematology, blood biochemistry, urinalysis, gross pathology, or histopathology. The no-observed-adverse-effect-level of Fenu-FG was 1,000 mg/kg/day. Furthermore, Fenu-FG did not demonstrate mutagenic potential up to a concentration of 5,000 µg/plate (Ames test) and did not induce structural chromosome aberrations up to 2,000 µg/ml (in human lymphocyte cells in vitro). In conclusion, Fenu-FG was found safe during preclinical safety assessments.
